ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO795

Safety of Erythropoietin Administration among ESRD Patients

Session Information

Category: Dialysis

  • 605 Dialysis: Anemia and Iron Metabolism


  • Lee, Jong hoon, Seoul St. Mary hospital, Seoul, Korea (the Republic of)
  • Chung, Byung ha, Seoul St. Mary hospital, Seoul, Korea (the Republic of)
  • Park, Cheol Whee, The Catholic University of Korea, Seoul, Korea (the Republic of)
  • Yang, Chul Woo, Seoul St. Mary's Hospital, Seoul, Korea (the Republic of)
  • Kim, Yong-Soo, The Catholic University of Korea College of Medicine, Seoul, Korea (the Republic of)
  • Choi, Bumsoon, Division of Nephrology, Department of Internal Medicine, Seoul, Korea (the Republic of)

Erythropoietin (EPO) has been used to care for anemia in CKD patients. Concerns about the administration of EPO include CVD events and tumor progression, but definite associations were not fully identified. We performed the study to validate safety of EPO administration among ESRD patients.


3432 ESRD patients were included to a prospective observational study in Clinical Research Center for ESRD registry. The patients were divided into HD group and PD group by dialysis methods. A dose of EPO, IV iron administration and serum Hb levels, CVD and cancer mortality were collected in the registry. Analyses were conducted to estimate hazard ratio(HR) for the EPO administration, dose of EPO and Hb levels with mortality of CVD and cancer.


The mortality rate of CVD was 1.71% in HD group and 1.94% in PD group. CVD mortality was increased by EPO administration in PD group (HR 1.72, p=0.04). But the mortality has no correlation with EPO dose and Hb level. Any factor did not relate to CVD mortality in HD group. The mortality rate of cancer in ESRD patients was 0.94% in HD group and 0.78% in PD group. Hb level, EPO administration and dose were not associated with cancer mortality in both groups. In multivariate risk factor analysis, the mortality of CVD was associated to diabetes (p<0.01) and age (p<0.01) in both groups. However, the mortality of cancer was not associated with any factor.


EPO administration was associated with an increase of CVD mortality in PD patients. Diabetes and age were independent risk factors of CVD mortality. On the other hand, the mortality of cancer in ESRD patients was not associated with EPO administration.

Cardiovascular disease survival among peritoneal dialysis patients